- Home
- LRE vs GNTA Comparison
LRE vs GNTA Comparison
Compare LRE & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | GNTA |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Japan | Italy |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 34.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LRE | GNTA |
|---|---|---|
| Price | $1.29 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.7K | ★ 92.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $1.28 |
| 52 Week High | $2.97 | $10.00 |
Technical Indicators
Market Signals| Indicator | LRE | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 34.68 |
| Support Level | $1.26 | $1.28 |
| Resistance Level | $1.45 | $1.68 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 16.22 | 21.08 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.